imatinib has been researched along with Hypertension, Pulmonary in 1 studies
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shaw, DE | 1 |
| Baig, F | 1 |
| Bruce, I | 1 |
| Chamoin, S | 1 |
| Collingwood, SP | 1 |
| Cross, S | 1 |
| Dayal, S | 1 |
| Drückes, P | 1 |
| Furet, P | 1 |
| Furminger, V | 1 |
| Haggart, D | 1 |
| Hussey, M | 1 |
| Konstantinova, I | 1 |
| Loren, JC | 1 |
| Molteni, V | 1 |
| Roberts, S | 1 |
| Reilly, J | 1 |
| Saunders, AM | 1 |
| Stringer, R | 1 |
| Sviridenko, L | 1 |
| Thomas, M | 1 |
| Thomson, CG | 1 |
| Tomlins, C | 1 |
| Wen, B | 1 |
| Yeh, V | 1 |
| Pearce, AC | 1 |
1 other study available for imatinib and Hypertension, Pulmonary
| Article | Year |
|---|---|
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension.
Topics: Administration, Inhalation; Airway Remodeling; Animals; Cell Line; Cell Proliferation; Hypertension, | 2016 |
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension.
Topics: Administration, Inhalation; Airway Remodeling; Animals; Cell Line; Cell Proliferation; Hypertension, | 2016 |